anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The objective of this randomized, double-blind study is to compare the effectiveness and safety of acetaminophen extended release caplets and ibuprofen in relieving the muscle soreness that occurs in subjects who complete a marathon. Subjects are randomized to receive acetaminophen extended release caplets, 3900 mg/day (two 650 mg caplets taken three times a day, for five days) or ibuprofen caplets, 1200 mg/day (two 200 mg caplets taken three times a day, for five days). The primary measurement of efficacy is the average change in muscle soreness from baseline for both the morning and evening assessments. Safety assessments consist of monitoring adverse events, and a physical examination including vital signs, weight, a review of concomitant medications, and a urine pregnancy test for female subjects. Two hypotheses are examined in a step-down approach. The first hypothesis is that acetaminophen extended release is not inferior to ibuprofen in relieving the muscle soreness that occurs after a marathon. If acetaminophen extended release is not inferior to ibuprofen in relieving the muscle soreness that occurs after a marathon, the second hypothesis is that acetaminophen extended release (3900 mg/day) is superior to ibuprofen (1200 mg/day) in relieving the muscle soreness that occurs after a marathon. Two acetaminophen 650 mg extended release caplets, taken by mouth, three times a day for five days or two ibuprofen 200 mg caplets, taken by mouth, three times a day for five days.
Frozen shoulder is among the most commonly reported problems to physicians, orthopedics and physical therapists. Even before reporting to clinics there is long history of using over the counter pain killers. Pain avoidance behaviors let the joint stiff so much that a clinician help is sought. Most times the cause of frozen shoulder is not known, therefore is termed as 'idiopathic frozen shoulder'.There is huge literature regarding the management of frozen shoulder and yet after the decades of research there are gaps in treatment options. In modern age of health care, it is common goal of every health care to make patient self-sufficient as early as possible. The self-care models have tremendous advantages. The current study has compared the use of theraband, co-contraction and isometric exercises. The current study was novel in a way that there is limited literature about treating shoulder hypomobility with physical strengthening exercises. All three methods were employed to see if they improve ranges along with accompanying pain and disability.
Catheter fixation will be performed after appropriate placement of a thoracic epidural with Dermabond. The investigator performing the thoracic epidural will distribute the Dermabond at the catheter insertion site in a space no greater than a 2 cm circle around the site. Once the Dermabond is allowed to dry, mastisol will be applied to the surrounding skin and a clear Tegaderm dressing will be used to cover the catheter. Catheter depth at the skin will be recorded at that time. An Epidural catheter infusion pump with 1/8thpercent Bupivacaine and 2mcg/ml Fentanyl will be attached to the catheter and started by the primary anesthesia with a goal rate of 6ml/hr.
Subjects with severe, subjective tinnitus due to sensorineural hearing loss will complete both TFI and THI surveys prior to starting therapy. Subjects will then be randomized to a treatment or placebo group. The treatment group will be provided with a supply of capsules containing 500 mg of curcumin-phosphatidylcholine combined with 250 mg of boswellia-phosphatidylcholine, which increases curcumin bioavailability. Subjects in the treatment arm will be instructed to take 1 capsule by mouth twice daily for 30 days. Placebo group subjects will be provided with a placebo compound with instructions to take the same number of capsules by mouth for the same period of time. Both the active compound and the placebo will be provided by Smartceuticals, Inc (910 W. Van Buren St. Ste 100-376 Chicago, IL 60607) to the outpatient pharmacy at Ascension Providence Park (Novi, MI), which will be responsible for storage, distribution and tracking. After 30 days, patients will be asked to return bottles to the pharmacy with any unused capsules to confirm and monitor compliance. Placebo and active agent capsules and bottles will be identical in appearance with the exception of a unique alphanumeric code on the bottle label that identifies whether the distributed capsules contain active agent or placebo. This code will be matched to the participating subject by the pharmacy and will be used at the end of the study to determine which treatment arm each subject was in. To facilitate blinding, the master list of alphanumeric codes will be maintained by the manufacturer. At the completion of therapy, subjects from both groups will re-take the TFI and THI.
PURPOSE: To treat the skin with uniform depth by a cylindrical dermal wound former which is kept in the main body by moving members pressed by spring when no force is applied from outside, and to which a proper load is applied by a load sensor when dermal wounds are to be formed. CONSTITUTION: A cylindrical dermal wound former 300 on the outer periphery of which a plurality of dermal needles are formed is supported movably in an up and down manner in a main body 330 with the rotary axes 302 at both ends borne in moving members 310. The moving members 310 are kept upward by spring members 322. Supporters 336 are formed on the outer side walls of the main body 330, regulating the moving range of a sub-body 340. Guides 314 formed on lower pushing members 343 formed as one-piece with the upper pressuring member 344 of the sub-body 340 contact the upper ends of the moving members 310. When the pressuring member 344 is pushed down, the dermal wounds former 300 projects from the body 330 to the outside to be ready for use.
All subjects will receive filgrastim as part of their primary mobilization regimen. If the subject meets minimum peripheral blood CD34+ cell count levels or adequately collects a threshold number of CD34+ cells, plerixafor will not be added to the mobilization regimen.
Since the early 2000's, digital reading applications have enhanced the language and literacy skills of typically hearing young children; however, no digital storybook intervention currently exists to scaffold the early language and literacy skills of their peers who are deaf or hard of hearing. To address this gap, our research team developed a novel digital storybook intervention called Hear Me Read with the aim of enhancing the therapeutic, language, and literacy benefits of speech-language therapy. This prospective clinical trial (registered at clinicaltrials.gov, NCT#: 05245799) aims to determine the efficacy of adding Hear Me Read to in-person speech-language therapy for children aged three to five years who are deaf or hard of hearing. Fifty caregivers, their child, and their child's treating speech-language pathologist participate in the trial for 12 months. In the first six months, children attend standard-of-care speech-language therapy sessions. In the second six months, children continue to attend standard-of-care speech-language therapy sessions and use the Hear Me Read application, via a study supplied iPad. The primary outcome of this trial is that, compared to in-person speech-language therapy alone, in-person speech-language therapy with Hear Me Read will improve vocabulary, speech, and language outcomes in children aged three to five years who are deaf or hard of hearing. The secondary outcome is that, compared to in-person speech-language therapy alone, in-person speech-language therapy with Hear Me Read will improve literacy outcomes in children aged three to five years who are deaf or hard of hearing. The goal of this intervention is to help children who are deaf or hard of hearing achieve their vocabulary, speech, language, and literacy goals through interactive digital storybook reading.
In recent decades, the prevalence of overweight and obesity has increased dramatically in developed countries. Obesity is associated with diseases such as diabetes, cardiovascular disease, hypertension, and certain cancers. Modest amounts of weight loss (e.g., 5% to 10% of initial body weight) significantly improve health and improve disease status. Recent evidence suggests that the use of supplements or meal replacements promotes greater weight loss than isocaloric food-based diets. In addition, diets that are high in protein are associated with greater ratings of satiety and reduced food intake, as well as greater weight loss, compared to lower protein diets.

The purpose of the proposed study is to test the effect of a partial supplement diet on body weight, body composition, and biomarkers for disease compared to an isocaloric diet that consists of a traditional food-based meal plan. Overweight and obese (BMI 25 to 35) participants will participate in this six-month study. The primary outcome variable is body weight loss and the secondary outcome variables include body composition, blood pressure, lipids, and subjective ratings of satiety.
The invention relates to a method for preparing a pharmaceutical natural surfactant, namely digalactosyldiacylglycerol (DGDG) and application thereof as a pharmaceutical carrier. The preparation technology thereof comprises the following steps: using acetone to extract oat bran, concentrating a leaching liquor and absorbing the concentrated leaching liquor by silica gel, using different polarities of eluents to elute the silica gel respectively, and finally obtaining refined DGDG in the eluents; or using carbon dioxide to supercritically degrease the oat bran first, then using the acetone for extraction, using the silica gel to absorb after an extracting solution is concentrated, and obtaining the refined DGDG after different polarities of eluents are used for elution. The hydrophile-lipophile balance value of the DGDG is between 7.00 and 8.15, and the critical micelle concentration is about 2*10<-3>g.L<-1>. The preparation method has cheap and easily-obtained raw materials, and the obtained DGDG is thin-layer chromatographically pure and has no hemolyticity and irritation. The DGDG has amphipathy, and can self-assemble to form double-layer vesicles in water, so that the DGDG can be taken as the pharmaceutical carrier. Galactose residues in DGDG molecules can be taken as a ligand, specifically identify galactose receptors on hepatic parenchymal cells, and realize ligand mediated active liver target.
Processes for making an antiperspirant emulsion composition and antiperspirant emulsion compositions are provided herein. In an embodiment, a process for making an antiperspirant emulsion composition includes combining water and an antiperspirant active component to form a water phase. A hydrophobic carrier and a structurant are combined to form an oil phase. The structurant has a melting point above ambient temperature. The oil phase is heated to a first temperature of at least a melting point of the structurant that is disposed in the oil phase. The water phase and the heated oil phase are mixed to form the antiperspirant emulsion composition. The antiperspirant emulsion composition is cooled under continued mixing.
Diastolic heart failure or heart failure with preserved systolic function is the leading cause of heart failure in elderly subjects (more than 2/3 of heart failure in subjects over 60 years). Its main etiology is high blood pressure. Diagnosis of diastolic heart failure remains controversial in clinical practice. It is based on ultrasound and biological criteria. These are mainly acute edema of the lung for patients with preserved Ejection Fraction and high Brain Natriuretic Peptid. It is now recognized that the "primum movens" of this type of heart failure is the increase in myocardial stiffness secondary to left ventricular hypertrophy. The noninvasive evaluation of this parameter would allow a more accurate and reliable diagnosis since it does not depend on the loading conditions, unlike the heart failure and the trans-mitral Doppler). However, the absence of a non-invasive tool for the direct evaluation of diastolic (so-called passive) rigidity prevents the use of this diagnostic parameter. Investigators propose here to non-invasively evaluate the myocardial stiffness in the elderly patient with diastolic heart failure thanks to a new imaging tool using an innovative ultrasonic technology, the ultrafast-echo associated with its elastographic mode "ShearWave Imaging". Investigators have been working for several years in collaboration with the Langevin Institute on this technology, which has recently been validated on experimental models. Its principle is based on the creation of a shear wave from a standard ultrasound probe and the calculation of the velocity of this wave thanks to the very high temporal resolution of the ultrasound system, this speed being correlated to the myocardial rigidity. The human study was recently made possible by the development of a phased array probe with the ability to work with the elastography mode ("ShearWave Imaging").
ABSTRACT OF THE DISCLOSURE        A clone of  Human  B  Lymphotropic  Virus  (HBLV), pZVH14  has  been  isolated  (from  the  peripheral blood leukocytes of six individuals)  and  characterized.   The clone  is  obtained  from  nucleic  acids  extracted from purified virus, and contains a 9.0 Kb HindIII fragment of HBLV .   HBLV contains a double-stranded DNA genome and is morphologically similar to some  members  of  the  Herpes family.    The   clone   is  lymphotropic and selectively infects freshly isolated human B cells, where it  induces the  appearance  of characteristic large refractile mono-nucleated or binucleated host cells.  The molecular clone of  the  present   invention  is  capable  of  in  situ hybridization with host cells infected with HBLV.   This clone,  therefore,  is  useful  as  a diagnostic probe  for HBLV-infected cells, as well as for the detection of viral antigens  or  antibodies  in  blood  samples  (using  an immunofluorescence assay or any other assay for antigens or antibodies which uses viral nucleic acids).  Molecular clone pZVH14 is also used in the detection of early virus infection of umbilical cord blood lymphocytes and spleen cells by in situ hybridization in culture.   The present invention is also capable of introducing genes into target cells  of  the virus  as  a  recombinant  DNA  virus  vector system.
Alzheimer's disease (AD) is a multifactorial,neurodegenerative disorder linked withextracellular amyloid beta (Aβ) plaques deposition and formation of intracellular neurofibrillary tangles (NFTs). Currently, no effective therapies are available to cure AD. Neuroinflammation isa well-known hallmark in the onset and advancement of AD and triggering receptor expressed on myeloid cells-2 (TREM-2), a microglial gene, is responsible for regulating inflammatory responses and clearance of cellular debris. Loss of TREM-2functionincreases neuroinflammation associated expression of pro-inflammatory markersthus resultingin reduced clearance of Aβ that further aid in disease progression.Therefore, targeting neuroinflammation is a good therapeutic approach for AD. This study aimed to determine the neuroprotective effect of nicotinic acid (NA) in vitro model of AD-like pathology induced in F-98 cell line using Phytohemagglutinin (PHA). MTT assay was employed for checking the cell viability as well as the proliferation of the cells following treatment with NA. PHA at the concentration of 10 μg/mL produces maximum plaques. The neuroprotective effect of NA was next evaluated against PHA-induced plaques and it was observed that NA reverses the damages induced by PHA i.e., by inhibiting the clustering of the cells and replacing the damaged cells with the new ones. Further, NA also increased the expression of TREM-2/DAP-12 with parallel decreased in the expression of IL-1β, TNF-α and iNOS. It also successfully altered disease associated ADAM-10 and BACE-1 compared to PHA control. These findings suggest that NA might be considered as a good therapeutic candidate for the treatment of neurodegenerative disorders like AD.
Post-chemotherapy, a small proportion of patients will not be deemed eligible for surgery by the treating physician (group C). Group C will be included in the evaluation of chemotherapy-related outcomes, and will also be asked to complete a follow-up visit 6 months from the end of their chemotherapy.
Comparing performance of conventional hearing aid fitting to Phonak's Bimodal Fitting formula using the Phonak Naida Link hearing aid. All patients are tested in a bimodal (hearing aid plus cochlear implant) setup. Initial tests are completed with the Advanced Bionics Naida Q70 or Q90 sound processor and the patient's own hearing aid. In this arm, a patient's own hearing aid is replaced with the Phonak Naida Link hearing aid to test if there is a benefit.
Standard lifetime carcinogenicity bioassays were conducted in mice and rats. Mice were given oral doses of zoledronic acid of 0.1, 0.5, or 2.0 mg/kg/day. There was an increased incidence of Harderian gland adenomas in males and females in all treatment groups (at doses greater than or equal to 0.002 times a human intravenous dose of 4 mg, based on a comparison of relative body surface areas). Rats were given oral doses of zoledronic acid of 0.1, 0.5, or 2.0 mg/kg/day. No increased incidence of tumors was observed (at doses less than or equal to 0.2 times the human intravenous dose of 4 mg, based on a comparison of relative body surface areas).

Zoledronic acid was not genotoxic in the Ames bacterial mutagenicity assay, in the Chinese hamster ovary cell assay, or in the Chinese hamster gene mutation assay, with or without metabolic activation. Zoledronic acid was not genotoxic in the in-vivo rat micronucleus assay. 

Female rats were given subcutaneous doses of zoledronic acid of 0.01, 0.03, or 0.1 mg/kg/day beginning 15 days before mating and continuing through gestation. Effects observed in the high-dose group (with systemic exposure of 1.2 times the human systemic exposure following an intravenous dose of 4 mg, based on AUC comparison) included inhibition of ovulation and a decrease in the number of pregnant rats. Effects observed in both the mid-dose group (with systemic exposure of 0.2 times the human systemic exposure following an intravenous dose of 4 mg, based on an AUC comparison) and high-dose group included an increase in preimplantation losses and a decrease in the number of implantations and live fetuses.
<P>PROBLEM TO BE SOLVED: To provide a manufacturing method that can manufacture a soft capsule of a simple composition having an excellent mechanical strength, preservability, transparency and moldability without using raw materials regarded as an additive.  <P>SOLUTION: Modified starch is prepared by subjecting waxy corn starch to acid treatment or wet heat treatment in the presence of a salt. A capsule film solution is prepared by dissolving 100 pts.wt. of the modified starch and 20-28 pts.wt. of iota carrageenan in water under heating. A capsule film made from the capsule film solution is treated in a rotary-die molding apparatus to mold the soft capsule filled with contents.  <P>COPYRIGHT: (C)2011,JPO&INPIT
PURPOSE:To provide the titled low-toxic agent containing L,DL-erythro-3-(3,4- dihydroxyphenyl)-serine or its salt as an active component, and capable of increasing the cerebral noradrenaline, thereby improving and curing the furor and catatonic schizophrenia. CONSTITUTION:The objective agent for suppressing psychokinetic excitation can be prepared by using L,DL-erythro-3-(3,4-dihydroxyphenyl)-serine (abbreviated as erythro-DOPS) or its salt as an active component. It has been found that erythro-DOPS has the effect to increase the cerebral noradrenaline level remarkably and suppress the excitation of noradrenergic nervous system. Accordingly, the present agent is effective for the improvement and remedy of symptoms corresponding to the furor and catatonic schizophrenia having the psychokinetic excitation as main symptom. It has no side effect in contrast to phenothiazine drug, butyrophenone drug, lithium agent, etc. and has low toxicity.
Hepatocellular carcinoma (HCC) is a malignant tumor with high incidence and mortality rates. NFKBIZ, a member of the nuclear factor kappa B inhibitory family, is closely related to tumor progression. However, the precise role of NFKBIZ in HCC remains unclear. To explore this, we conducted a series of experiments from clinic to cells. Western blot and qPCR revealed a significant downregulation of NFKBIZ in human HCC tissues. Clinical character analysis showed that the patients with lower NFKBIZ expression had poorer prognosis and higher clinical stage. By using CCK-8, wound healing, transwell invasion and migration assay, we discovered that NFKBIZ expression was reversely associated with the proliferation, invasion, and migration ability of HCC cells in vitro. Additionally, the results obtained from xenograft assay and lung metastasis models showed that NFKBIZ overexpression inhibited the growth and metastasis of HCC cells in vivo. Western blot and immunofluorescence assay further revealed that NFKBIZ mediated HCC cell growth and migration by regulating NFκB signaling transduction. Finally, flow cytometry, protein degradation assay and Co-immunoprecipitation indicated that TRIM16 can enhance NFKBIZ ubiquitination by direct interactions at its K48 site, which may thereby alleviate HCC cell apoptosis to induce the insensitivity to sorafenib. In conclusion, our study demonstrated that NFKBIZ regulated HCC tumorigenesis and metastasis by mediating NFκB signal transduction and TRIM16/NFKBIZ/NFκB axis may be the underlying mechanism of sorafenib insensitivity in HCC.
FIELD: organic chemistry. SUBSTANCE: product: derivatives of 1,4-benzodioxane of the formula (I) given in description text at definite radical values, or their salt and a method of their synthesis. Reagent 1: compound of the formula (II) B-Q-X′, where X′=X or NH 2 -group where X - chlorine, bromine or iodine atom, hydroxy-group or its reactive derivative. Reagent 2: compound of the formula (III) given in description text where X 2  and X 3  can have similar or different values; if X′-NH 2  group then every of X 2  and X 3  has value X; in opposite case X 2  and X 3  together form NH-group. Capability of synthesized compounds to inhibit the binding of tritium-labeled serotonine ligands with hippocampus receptors is investigated. Synthesized compounds were used in medicine. EFFECT: improved method of synthesis. 4 cl